Total ban on the use of adverse genetic testing results in life insurance
Posted: 12 September 2024 The Albanese Government will end the ability to discriminate based on adverse predictive genetic test results by banning their use in life insurance underwriting. Genetic testing can be a life‑saving step for members of…
New medicines could be PBS-listed in just four weeks under a proposal the health minister calls ‘visionary’
Posted: 12 September 2024 Have you ever had to wait for an important and expensive medicine to be subsidised? A new independent review aims to address what has been a longstanding issue in the health system as part…
First Specialist Paediatric Clinical Site Activated, Recruitment Update & Key Appointment
Posted: 12 September 2024 Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, is pleased to advise that the first clinical site specialising in paediatric kidney disease was activated today in…
World-first Florey research aims to rapidly and accurately screen drugs to treat MND
Posted: 12 September 2024 Florey MND researchers are poised to begin large-scale drug screening of potential treatments for MND thanks to a $5 million grant from the Australian Medical Research Future Fund (MRFF). Project leader Dr Chris Bye…
CUREator Incubator Fuels Biotech with $1.865M Funding
Posted: 11 September 2024 CUREator, Australia’s national biotech incubator managed by Brandon BioCatalyst, today announced that four companies will receive top-up funding across their Preclinical and Health Security streams. Top-up funding rounds are supplemented with monies from projects…
AusBiotech appoints Industry Growth Program Manager
Posted: 11 September 2024 AusBiotech is pleased to announce the appointment of Tamlyn O’Connor as its new Industry Growth Program Manager. Tamlyn will deliver AusBiotech’s ‘Innovation Activation Program’ for Australian biotech and medtech SMEs that are part of…
First Patient Enters DMX-200 Open Label Extension Study After Successfully Completing ACTION3 Phase 3 Trial
Posted: 10 September 2024 Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, today announced that the first patient has successfully completed the ACTION3 Phase 3 clinical trial, including the initial…
PAT-DX1 GMP specification testing update
Posted: 4 September 2024 Patrys Limited a therapeutic antibody development company, provides the following update regarding the recently completed GMP manufacturing run of PAT-DX1. Patrys’ Contract Development Manufacturing Organization (CDMO) has advised the Company that specification testing using…
NUKED – a special investigation into the radiopharmaceuticals industry
Posted: 4 September 2024 Debuting at number four on Apple Podcasts Australia in the Life Sciences category, the Phase III podcast is now sharing its second deep-dive series on the sector. The NUKED series explores the growth in…
Man who could save Australia’s koalas honoured with Qld life science award
Posted: 4 September 2024 The creator of a vaccine that has the potential to prevent Australia’s koala population being decimated by chlamydia has been awarded a top biotechnology award in a ceremony in Brisbane on Friday. Professor Peter…
Significant results from new brain cancer drugs as Chroma platform matures
Posted: 4 September 2024 Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to announce substantial progress on its Chroma™ technology platform, with encouraging brain cancer results plus early work on leukaemia. Glioblastoma is the most frequent and lethal…
Blood stem cell breakthrough could transform bone marrow transplants
Posted: 3 September 2024 Melbourne researchers have made a world first breakthrough into creating blood stem cells that closely resemble those in the human body. And the discovery could soon lead to personalised treatments for children with leukaemia…
